Clinical trials: Hepatic
Elevated Triglycerides, Diabetes
Change of Fructose to Fat in South Asians
The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).
- Conditions
- Elevated Triglycerides, Diabetes, Cardiovascular Disease, Dyslipidemia
- Trial name
- NCT01562782
- Testing
- Fructose + Glucose Beverage
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- The Rogosin Institute
Fatty Liver, Fatty Liver, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver…
- Trial name
- NCT04462562
- Testing
- Quantitative US (Samsung Medison, RS85A)
- Where
- South Korea
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatic Impairment, Healthy Volunteers
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.
- Trial name
- NCT04942964
- Testing
- Bocidelpar
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Hepatic Impairment
Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment
Determine the influence of hepatic impairment on the pharmacokinetics and metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg capsules
- Trial name
- NCT02242734
- Testing
- 20 mg HC-ER
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zogenix, Inc.
Healthy Volunteer, Hepatic Impairment
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
- Trial name
- NCT05724693
- Testing
- Bemnifosbuvir (BEM)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Health Behavior
Effects of a Patient Directed Web-portal to Improve Health Literacy Skills
Access to the best available evidence, and the ability to obtain and understand such information is seen as necessary to protect the public's interests and critical to empowerment, but is also a precondition for participation in…
- Trial name
- PREP (NCT01266798)
- Testing
- Portal
- Where
- Norway
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Oslo Metropolitan University
Type2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
The purpose of this study is to examine the drug exposure and drug effects on subjects with moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg.
- Trial name
- NCT03557658
- Testing
- Bexagliflozin
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Theracos
Healthy
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
This study will assess the influence of moderate hepatic impairment on the pharmacokinetics of licarbazepine after single oral administration in healthy subjects and in subjects with stable impaired hepatic function.
- Trial name
- NCT00424671
- Testing
- Licarbazepine
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis
Handgrip Strength, Transjugular Intrahepatic Portosystemic Shunts (TIPS)
Handgrip Strength Increases the Pressure in the Portal and Left Gastric Veins in Cirrhotic Patients
1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis.
- Trial name
- NCT07289698
- Testing
- Handgrip strength
- Where
- 2 sites in China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanxi Provincial People's Hospital
Hepatic Impairment, Healthy Adult Participants
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment
The goal of this study is to understand how the body processes tacabrutideg in adults with different levels of liver function (normal, moderate impairment, and severe impairment).
- Trial name
- NCT07856004
- Testing
- Tacabrutideg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Visceral Obesity, Non-Alcoholic Fatty Liver Disease
Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity
The aim of this study is to validate the efficacy of specific combination of different natural histidine-related amino acids in the reduction of visceral fat and liver steatosis, as well their associated comorbidities, in…
- Trial name
- FATHIS (NCT05807204)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Hepatic Impairment
Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment
To assess pharamcokinetics, safety and tolerability of a single oral dose of BKM120 in subjects with mild, moderate and severe hepatic impairment
- Trial name
- NCT01727128
- Testing
- BKM120
- Where
- 3 sites in Bulgaria, Germany and 1 more
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hepatic Impairment; Renal Impairment
Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants.
- Trial name
- NCT02998775
- Testing
- Plasma Sampling
- Where
- 3 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Hepatic Impairment
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic…
- Trial name
- NCT05935033
- Testing
- Emraclidine
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy, Hepatic Impairment
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
The purposes of this study are to determine: The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body…
- Trial name
- NCT06997276
- Testing
- Mirdametinib (MEK Inhibitor)
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Identify More Accurate Predictive Models of Transplant Risk to Monitor and Evaluate New and Existing Patient Factors
Hepatic Transplantation Registry
The objective is to provide a mechanism to store information regarding the demographic characteristics; pre-, intra-, and post-transplant laboratories; treatment strategies; complications; and outcomes in patients undergoing…
- Trial name
- NCT05944042
- Testing
- Observational Transplant Analysis
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Methodist Health System
Subjects With Liver Function Injury, Normal Liver Function Subject
A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical…
- Trial name
- NCT06093230
- Testing
- Deuremidevir Hydrobromide Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Hepatic Impairment
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following…
- Trial name
- NCT05467722
- Testing
- CTP-543
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes, Dyslipidemia
Effects of Metformin on Hepatic FFA Metabolism
Background: Metformin treatment has beneficial effects on both glucose and lipid metabolism. Whereas there is general agreement that the blood glucose lowering effect of metformin results from inhibition of hepatic…
- Trial name
- NCT01729156
- Testing
- Metformin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lars Christian Gormsen